Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017.
Sign Up to like & getrecommendations! Published in 2020 at "AIDS"
DOI: 10.1097/qad.0000000000002679
Abstract: OBJECTIVE Historically, a high burden of resistance to antiretroviral therapy (ART) in heavily treatment experienced (HTE) persons with HIV (PWH) resulted in limited treatment options (LTO). We evaluated the prevalence, risk factors, and virologic control… read more here.
Keywords: treatment; lto; treatment experienced; heavily treatment ... See more keywords
Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV
Sign Up to like & getrecommendations! Published in 2022 at "HIV Medicine"
DOI: 10.1111/hiv.13288
Abstract: Entry inhibitors are a relatively new class of antiretroviral therapy and are typically indicated in heavily treatment experienced individuals living with HIV. Despite this, there is no formal definition of ‘heavily treatment experienced’. Interpretation of… read more here.
Keywords: entry inhibitors; individuals living; treatment; treatment experienced ... See more keywords
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01751-21
Abstract: In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1 RNA read more here.
Keywords: phase brighte; brighte study; treatment; treatment experienced ... See more keywords